Purification of vaccinia viruses using hydrophobic interaction chromatography

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention provides a method for purifying Vaccinia viruses using hydrophobic interaction chromatography. The process results in highly pure and stable virus preparations that retain biological activity, making the viruses suitable for industrial-scale applications and further use.

Use CasesContent extracted from patent full text and abstract with AI.

• Production of vaccines based on Vaccinia virus, such as smallpox or monkeypox vaccines
• Manufacturing of viral vectors for gene therapy or cancer treatment
• Production of research-grade Vaccinia virus for laboratory studies
• Development of safer and more effective viral therapies for a range of diseases

BenefitsContent extracted from patent full text and abstract with AI.

• Enables highly pure and stable virus preparations, reducing contamination risks
• Maintains biological activity of the purified virus, ensuring effectiveness
• Scalable and efficient for industrial production, supporting large-scale vaccine or therapeutic manufacturing
• Improved sterilization reduces the risk of unwanted pathogens or impurities
• Increases overall yield, which is cost-effective and beneficial for vaccine accessibility

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to methods for purification of Vaccinia viruses (VV) and/or Vaccinia virus (VV) particles, which can lead to highly pure and stable virus preparations of predominantly biologically active viruses. The invention encompasses purifying a virus preparation in a sterilized way with high efficiency and desirable yield in terms of purity, biological activity and stability, aspects advantageous for industrial production.